Opioid-induced bowel dysfunction: Pathophysiology and management

Drugs

Volumn 72, Issue 14, 2012, Pages 1847-1865

  Brock, Christina ^a   Olesen, Søren Schou ^a   Olesen, Anne Estrup ^a   Frøkjaer, Jens Brøndum ^a   Andresen, Trine ^a   Drewes, Asbjørn Mohr ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

ADL 7445; Alvimopan; Analgesics; Bevenopran; Buprenorphine; Constipation; Fentanyl; Gastrointestinal disorders; Gastrointestinal motility; Laxatives; Lubiprostone; Methylnaltrexone bromide; Naloxegol; Naloxone; Opioid analgesics; Opioid receptor antagonists; Oxycodone; Oxycodonenaloxone; Prucalopride; Quality of life; Tapentadol; TD 1211; Transdermal

Indexed keywords

17 METHYLNALTREXONE BROMIDE; ADL 5945; ADL 7445; ALKS 37; ALVIMOPAN; ANIONIC SURFACTANT; BISACODYL; BUPRENORPHINE; FENTANYL; ISPAGULA; LACTULOSE; LAXATIVE; LUBIPROSTONE; MACROGOL; MAGNESIUM; METHYLCELLULOSE; MORPHINE; NALOXONE; NALOXONE PLUS OXYCODONE; NKTR 118; OPIATE; OPIATE ANTAGONIST; OSMOTIC AGENT; OXYCODONE; PROKINETIC AGENT; PRUCALOPRIDE; SEROTONIN 4 ANTAGONIST; TAPENTADOL; TD 1211; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ABNORMAL FECES; ACIDOSIS; ANORECTAL DISEASE; ANOREXIA; ANUS SPHINCTER; BILIARY COLIC; BLOATING; BOWEL FUNCTION INDEX; BRISTOL STOOL CHART; CANCER PAIN; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DIETARY FIBER; DIGESTIVE SYSTEM PERFORATION; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DYSPHAGIA; ELECTROLYTE DISTURBANCE; ENTEROPATHY; EPIGASTRIC DISCOMFORT; EPIGASTRIC PAIN; FECES IMPACTION; FLUID INTAKE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SECRETION; GASTROINTESTINAL SYMPTOM; HARD FECES; HEARTBURN; HUMAN; ILEOCECAL VALVE; INTESTINE INNERVATION; INTESTINE TRANSIT TIME; LOWER ESOPHAGUS SPHINCTER; MANOMETRY; NAUSEA; NONHUMAN; ODDI SPHINCTER; OPIATE ADDICTION; OPIOID INDUCED BOWEL DYSFUNCTION; PAIN; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT ASSESSMENT OF CONSTIPATION AND QUALITY OF LIFE QUESTIONNAIRE; PRESCRIPTION; PREVALENCE; REVIEW; SEDATION; SENNA; SENSORY NERVE; SIDE EFFECT; SYMPTOMATOLOGY; URINE RETENTION; VISCERAL PAIN; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANALGESICS, OPIOID; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HUMANS; NARCOTIC ANTAGONISTS; SEVERITY OF ILLNESS INDEX;

EID: 84866102685     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11634970-000000000-00000     Document Type: Review

References (144)

1. Trescot AM, Glaser SE, Hansen H, et al. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician 2008 Mar; 11 (2 Suppl.): S181-200 (Pubitemid 351682085)
2. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182 (5): S11-8
3. Loostrom H, Akerman S, Ericson D, et al. Tramadolinduced oral dryness and pilocarpine treatment: effects on total protein and IgA. Arch Oral Biol 2011 Apr; 56 (4): 395-400
4. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63 (7): 649-71 (Pubitemid 36408072)
5. Thorpe DM. Management of opioid-induced constipation. Curr Pain Headache Rep 2001 Jun; 5 (3): 237-40
6. Tamayo AC, Diaz-Zuluaga PA. Management of opioidinduced bowel dysfunction in cancer patients. Support Care Cancer 2004 Sep; 12 (9): 613-8 (Pubitemid 39280310)
7. Costa M, Brookes JH. The enteric nervous system. Am J Gastroenterol 1994; 89 (8): 129-37
8. Gershon MD. The enteric nervous system. Annu Rev Neurosci 1981; 4 (1): 227-72
9. Aziz Q, Thompson DG. Brain-gut axis in health and disease. Gastroenterology 1998 Mar; 114 (3): 559-78 (Pubitemid 28141202)
10. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage 2008; 35: 103-13 (Pubitemid 350299099)
11. Janig W. Integration of gut function by sympathetic reflexes. Baillieres Clin Gastroenterol 1988 Jan; 2 (1): 45-62
12. Wood JD. Enteric nervous system: sensory physiology, diarrhea and constipation. Curr Opin Gastroenterol 2010 Mar; 26 (2): 102-8
13. Furness JB, Kunze WA, Bertrand PP, et al. Intrinsic primary afferent neurons of the intestine. Prog Neurobiol 1998 Jan; 54 (1): 1-18 (Pubitemid 28049816)
14. Sternini C, Patierno S, Selmer IS, et al. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004 Oct; 16 Suppl. 2: 3-16 (Pubitemid 39468862)
15. Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 2007 Feb; 16 (2): 181-94 (Pubitemid 46206632)
16. Huizinga JD, Lammers WJ. Gut peristalsis is governed by a multitude of cooperating mechanisms. Am J Physiol Gastrointest Liver Physiol 2009 Jan; 296 (1): G1-8
17. Mikkelsen HB. Interstitial cells of Cajal, macrophages and mast cells in the gut musculature: morphology, distribution, spatial and possible functional interactions. J Cell Mol Med 2010 Apr; 14 (4): 818-32
18. Galligan JJ, Burks TF. Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Exp Ther 1983 Aug; 226 (2): 356-61 (Pubitemid 13041507)
19. Thorn SE, Wattwil M, Lindberg G, et al. Systemic and central effects of morphine on gastroduodenal motility. Acta Anaesthesiol Scand 1996 Feb; 40 (2): 177-86 (Pubitemid 26063250)
20. Viscusi ER, Gan TJ, Leslie JB, et al. Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability. Anesth Analg 2009 Jun; 108 (6): 1811-22
21. Bianchi G, Ferretti P, Recchia M, et al. Morphine tissue levels and reduction of gastrointestinal transit in rats: correlation supports primary action site in the gut. Gas-troenterology 1983 Oct; 85 (4): 852-8 (Pubitemid 13000637)
22. Fioravanti B, Vanderah TW. The ORL-1 receptor system: are there opportunities for antagonists in pain therapy? Curr Top Med Chem 2008; 8 (16): 1442-51
23. Greenwood-Van MB, Gardner CJ, Little PJ, et al. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 2004 Oct; 16 Suppl. 2: 46-53 (Pubitemid 39468866)
24. Jordan B, Devi LA. Molecular mechanisms of opioid receptor signal transduction. Br J Anaesth 1998 Jul; 81 (1): 12-9 (Pubitemid 28359261)
25. Sharma SK, Nirenberg M, Klee WA. Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci USA 1975; 72 (2): 590-4
26. Sarna SK, Otterson MF. Small intestinal amyogenesia and dysmyogenesia induced by morphine and loperamide. Am J Physiol 1990 Feb; 258 (2 Pt 1): G282-9 (Pubitemid 20095438)
27. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004 Oct; 16 Suppl. 2: 17-28 (Pubitemid 39468863)
28. Kraichely RE, Arora AS, Murray JA. Opiate-induced oesophageal dysmotility. Aliment Pharmacol Ther 2010 Mar; 31 (5): 601-6
29. Telford GL, Condon RE, Szurszewski JH. Opioid receptors and the initiation of migrating myoelectric complexes in dogs. Am J Physiol 1989 Jan; 256 (1 Pt 1): G72-7
30. Frantzides CT, Cowles V, Salaymeh B, et al. Morphine effects on human colonic myoelectric activity in the postoperative period. Am J Surg 1992 Jan; 163 (1): 144-8
31. Cooke HJ. "Enteric tears": chloride secretion and its neural rRegulation. News Physiol Sci 1998 Dec; 13: 269-74
32. Murek M, Kopic S, Geibel J. Evidence for intestinal chloride secretion. Exp Physiol 2010 Apr; 95 (4): 471-8
33. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol 2000; 62: 535-72 (Pubitemid 30618274)
34. Clarke LL, Harline MC. CFTR is required for cAMP inhibition of intestinal Na+ absorption in a cystic fibrosis mouse model. Am J Physiol 1996 Feb; 270 (2 Pt 1): G259-67
35. Kunzelmann K. The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol 1999; 137: 1-70
36. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 2002 Jan; 82 (1): 245-89 (Pubitemid 34654220)
37. Glad H, Ainsworth MA, Svendsen P, et al. Effect of vasoactive intestinal peptide and pituitary adenylate cy-clase-activating polypeptide on pancreatic, hepatic and duodenal mucosal bicarbonate secretion in the pig. Digestion 2003; 67 (1-2): 56-66 (Pubitemid 36570304)
38. De LA, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996; 69 (2): 103-15 (Pubitemid 26111425)
39. Toouli J. Sphincter of Oddi: function, dysfunction, and its management. J Gastroenterol Hepatol 2009 Oct; 24 Suppl. 3: S57-62
40. Penagini R, Bartesaghi B, Zannini P, et al. Lower oesophageal sphincter hypersensitivity to opioid receptor stimulation in patients with idiopathic achalasia. Gut 1993 Jan; 34 (1): 16-20 (Pubitemid 23015943)
41. Sharma SS. Sphincter of Oddi dysfunction in patients addicted to opium: an unrecognized entity. Gastrointest Endosc 2002 Mar; 55 (3): 427-30 (Pubitemid 41115163)
42. Torres D, Parrinello G, Trapanese C, et al. Sudden severe abdominal pain after a single low dose of para-cetamol/codein in a cholecystectomized patient: learning from a case report. Am J Ther 2010 Jul; 17 (4): e133-4
43. Nardi GL, Acosta JM. Papillitis as a cause of pancreatitis and abdominal pain: role of evocative test, operative pancreatography and histologic evaluation. Ann Surg 1966 Oct; 164 (4): 611-21
44. Lobo DN, Takhar AS, Thaper A, et al. The morphineprostigmine provocation (Nardi) test for sphincter of Oddi dysfunction: results in healthy volunteers and in patients before and after transduodenal sphincteroplasty and transampullary septectomy. Gut 2007 Oct; 56 (10): 1472-3 (Pubitemid 47517848)
45. Tuteja AK, Biskupiak J, Stoddard GJ, et al. Opioidinduced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogas-troenterol Motil 2010 Apr; 22 (4): 424-30, e96
46. Choung RS, Locke III GR, Zinsmeister AR, et al. Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. Am J Gastroenterol 2009 May; 104 (5): 1199-204
47. Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care 2006 Jun; 23 (3): 229-35
48. Bril S, Shoham Y, Marcus J. The 'mystery' of opioidinduced diarrhea. Pain Res Manag 2011 May; 16 (3): 197-9
49. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003 Oct 2; 349 (14): 1360-8
50. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004 May; 11 (3 Suppl.): 3-9 (Pubitemid 38756665)
51. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999 Dec; 94 (12): 3530-40
52. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007 Mar 1; 25 (5): 599-608
53. Connell AM, Hilton C, Irvine G, et al. Variation of bowel habit in two population samples. Br Med J 1965 Nov 6; 2 (5470): 1095-9
54. Koch A, Voderholzer WA, Klauser AG, et al. Symptoms in chronic constipation. Dis Colon Rectum 1997 Aug; 40 (8): 902-6 (Pubitemid 27355391)
55. Sandler RS, Drossman DA. Bowel habits in young adults not seeking health care. Dig Dis Sci 1987 Aug; 32 (8): 841-5 (Pubitemid 17118850)
56. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006 Apr; 130 (5): 1480-91
57. Wald A. Chronic constipation: advances in management. Neurogastroenterol Motil 2007; 19 (1): 4-10 (Pubitemid 44952773)
58. Camilleri M, Bharucha AE. Behavioural and new pharmacological treatments for constipation: getting the balance right. Gut 2010 Sep; 59 (9): 1288-96
59. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci 1989 Apr; 34 (4): 606-11 (Pubitemid 19122000)
60. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001 Nov; 96 (11): 3130-7 (Pubitemid 33095352)
61. Ragg J, McDonald R, Hompes R, et al. Isolated colonic inertia is not usually the cause of chronic constipation. Colorectal Dis 2011 Nov; 13 (11): 1299-302
62. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005; 7 (5): R1046-51
63. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009 Jan; 10 (1): 35-42
64. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001 May 12; 322 (7295): 1154-8 (Pubitemid 32434223)
65. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004 Dec; 112 (3): 372-80 (Pubitemid 39550738)
66. Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther 2008 Jun; 27 (12): 1224-32 (Pubitemid 351697276)
67. Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum 1996 Jun; 39 (6): 681-5 (Pubitemid 26181138)
68. Kamm MA, Dudding TC, Melenhorst J, et al. Sacral nerve stimulation for intractable constipation. Gut 2010 Mar; 59 (3): 333-40
69. McMillan SC, Williams FA. Validity and reliability of the Constipation Assessment Scale. Cancer Nurs 1989 Jun; 12 (3): 183-8 (Pubitemid 19197864)
70. Varma MG, Wang JY, Berian JR, et al. The constipation severity instrument: a validated measure. Dis Colon Rectum 2008 Feb; 51 (2): 162-72
71. Goodman M, Low J, Wilkinson S. Constipation management in palliative care: a survey of practices in the United Kingdom. J Pain Symptom Manage 2005 Mar; 29 (3): 238-44 (Pubitemid 40386740)
72. Downing GM, Kuziemsky C, Lesperance M, et al. Development and reliability testing of the Victoria Bowel Performance Scale (BPS). J Pain Symptom Manage 2007 Nov; 34 (5): 513-22 (Pubitemid 47633899)
73. Hawley P, Barwich D, Kirk L. Implementation of the Victoria Bowel Performance Scale. J Pain Symptom Manage 2011 Dec; 42 (6): 946-53
74. Olesen AE, Drewes AM. Validated tools for evaluating opioid-induced bowel dysfunction. Adv Ther 2011 Apr; 28 (4): 279-94
75. Rentz AM, Yu R, Muller-Lissner S, et al. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12 (4): 371-83
76. Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999 Sep; 34 (9): 870-7 (Pubitemid 29470564)
77. Slappendel R, Simpson K, Dubois D, et al. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006 Apr; 10 (3): 209-17 (Pubitemid 43255207)
78. Marquis P, De La LC, Dubois D, et al. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005 May; 40 (5): 540-51 (Pubitemid 40676247)
79. Dubois D, Gilet H, Viala-Danten M, et al. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil 2010 Feb; 22 (2): e54-63
80. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997 Sep; 32 (9): 920-4 (Pubitemid 27382038)
81. Saad RJ, Rao SS, Koch KL, et al. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol 2010 Feb; 105 (2): 403-11
82. Ashraf W, Park F, Lof J, et al. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol 1996 Jan; 91 (1): 26-32 (Pubitemid 26026032)
83. Dinning PG, Smith TK, Scott SM. Pathophysiology of colonic causes of chronic constipation. Neurogas-troenterol Motil 2009 Dec; 21 Suppl. 2: 20-30
84. Starreveld JS, Pols MA, Van Wijk HJ, et al. The plain abdominal radiograph in the assessment of constipation. Z Gastroenterol 1990 Jul; 28 (7): 335-8 (Pubitemid 20274808)
85. Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol Clin North Am 2007 Sep; 36 (3): 687-711, x (Pubitemid 47575844)
86. Bharucha AE, Phillips SF. Slow transit constipation. Gastroenterol Clin North Am 2001 Mar; 30 (1): 77-95 (Pubitemid 32488438)
87. Metcalf AM, Phillips SF, Zinsmeister AR, et al. Simplified assessment of segmental colonic transit. Gastroenterology 1987 Jan; 92 (1): 40-7 (Pubitemid 17207659)
88. Evans RC, Kamm MA, Hinton JM, et al. The normal range and a simple diagram for recording whole gut transit time. Int J Colorectal Dis 1992 Feb; 7 (1): 15-7
89. Hawkes ND, Richardson C, Evans BK, et al. Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine. Aliment Pharmacol Ther 2001 May; 15 (5): 625-30 (Pubitemid 32385866)
90. Reber PU, Netzer P, Gaia C, et al. Influence of naloxone on gastric emptying of solid meals, myoelectrical gastric activity and blood hormone levels in young healthy volunteers. Neurogastroenterol Motil 2002 Oct; 14 (5): 487-93 (Pubitemid 35216331)
91. Netzer P, Gaia C, Lourens ST, et al. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? Aliment Pharmacol Ther 2002 Jan; 16 (1): 119-27 (Pubitemid 34123872)
92. Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989 Aug; 257 (2 Pt 1): G284-90
93. Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992 Jul; 103 (1): 36-42
94. Proano M, Camilleri M, Phillips SF, et al. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol 1990 Jun; 258 (6 Pt 1): G856-62 (Pubitemid 20215935)
95. Proano M, Camilleri M, Phillips SF, et al. Unprepared human colon does not discriminate between solids and liquids. Am J Physiol 1991 Jan; 260 (1 Pt 1): G13-6
96. Stivland T, Camilleri M, Vassallo M, et al. Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology 1991 Jul; 101 (1): 107-15
97. Gonenne J, Camilleri M, Ferber I, et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005 Aug; 3 (8): 784-91 (Pubitemid 41116731)
98. Burton DD, Camilleri M, Mullan BP, et al. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997 Nov; 38 (11): 1807-10 (Pubitemid 27495535)
99. Zhang WQ, Yan GZ, Ye DD, et al. Simultaneous assessment of the intraluminal pressure and transit time of the colon using a telemetry technique. Physiol Meas 2007 Feb; 28 (2): 141-8 (Pubitemid 46646337)
100. Rao SS, Kuo B, McCallum RW, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gas-troenterol Hepatol 2009 May; 7 (5): 537-44
101. Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci 2009 Oct; 54 (10): 2167-74
102. Hiroz P, Schlageter V, Givel JC, et al. Colonic movements in healthy subjects as monitored by a Magnet Tracking System. Neurogastroenterol Motil 2009 Aug; 21 (8): 838-e57
103. Stathopoulos E, Schlageter V, Meyrat B, et al. Magnetic pill tracking: a novel non-invasive tool for investigation of human digestive motility. Neurogastroenterol Motil 2005 Feb; 17 (1): 148-54 (Pubitemid 40204022)
104. Fynne L, Worsoe J, Gregersen T, et al. Gastrointestinal transit in patients with systemic sclerosis. Scand J Gas-troenterol 2011 Oct; 46 (10): 1187-93
105. Brookes SJ, Dinning PG, Gladman MA. Neuroanatomy and physiology of colorectal function and defaecation: from basic science to human clinical studies. Neurogas-troenterol Motil 2009 Dec; 21 Suppl. 2: 9-19
106. Cook IJ, Talley NJ, Benninga MA, et al. Chronic constipation: overview and challenges. Neurogastroenterol Motil 2009 Dec; 21 Suppl. 2: 1-8
107. Gladman MA, Lunniss PJ, Scott SM, et al. Rectal hyposensitivity. Am J Gastroenterol 2006 May; 101 (5): 1140-51 (Pubitemid 43725332)
108. Rao SS. Constipation: evaluation and treatment. Gastroenterol Clin North Am 2003 Jun; 32 (2): 659-83 (Pubitemid 36807587)
109. Lunniss PJ, Gladman MA, Benninga MA, et al. Pathophysiology of evacuation disorders. Neurogastroenterol Motil 2009 Dec; 21 Suppl. 2: 31-40
110. Rao SS, Hatfield R, Soffer E, et al. Manometric tests of anorectal function in healthy adults. Am J Gastroenterol 1999 Mar; 94 (3): 773-83 (Pubitemid 29124880)
111. Mortele KJ, Fairhurst J. Dynamic MR defecography of the posterior compartment: indications, techniques and MRI features. Eur J Radiol 2007 Mar; 61 (3): 462-72 (Pubitemid 46274142)
112. Gregersen H, Kassab G. Biomechanics of the gastrointestinal tract. Neurogastroenterol Motil 1996 Dec; 8 (4): 277-97 (Pubitemid 26405474)
113. Dall FH, Jorgensen CS, Houe D, et al. Biomechanical wall properties of the human rectum: a study with impedance planimetry. Gut 1993 Nov; 34 (11): 1581-6 (Pubitemid 23341852)
114. Andersen IS, Gregersen H, Buntzen S, et al. New probe for the measurement of dynamic changes in the rectum. Neurogastroenterol Motil 2004 Feb; 16 (1): 99-105 (Pubitemid 38253526)
115. McMahon BP, Frokjaer JB, Liao D, et al. A new technique for evaluating sphincter function in visceral organs: application of the functional lumen imaging probe (FLIP) for the evaluation of the oesophago-gastric junction. Physiol Meas 2005 Oct; 26 (5): 823-36 (Pubitemid 41140799)
116. Frokjaer JB, Liao D, Bergmann A, et al. Three-dimensional biomechanical properties of the human rectum evaluated with magnetic resonance imaging. Neurogastroenterol Motil 2005 Aug; 17 (4): 531-40 (Pubitemid 41075995)
117. Osterbrink J, Haas U. Opioid-induced bowel dysfunction: a literature analysis on pathophysiology and treatment [in German]. Wien Med Wochenschr 2008; 158 (21-22): 621-6
118. Herndon CM, Jackson KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 2002 Feb; 22 (2): 240-50 (Pubitemid 34112884)
119. Diego L, Atayee R, Helmons P, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs 2011 Aug; 20 (8): 1047-56
120. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioidinduced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007 Jul; 61 (7): 1181-7 (Pubitemid 46934629)
121. Wong BS, Camilleri M. Lubiprostone for the treatment of opioid-induced bowel dysfunction. Expert Opin Pharma-cother 2011 Apr; 12 (6): 983-90
122. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011 May; 106 (5): 835-42
123. Meissner W, Schmidt U, Hartmann M, et al. Oral naloxone reverses opioid-associated constipation. Pain 2000 Jan; 84 (1): 105-9
124. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996 Apr; 10 (2): 135-44 (Pubitemid 26110994)
125. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008 Dec; 9 (12): 1144-54
126. Kraft MD. Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. Expert Opin Investig Drugs 2008 Sep; 17 (9): 1365-77
127. Yu CS, Chun HK, Stambler N, et al. Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials. Dis Colon Rectum 2011 May; 54 (5): 570-8
128. Chappell D, Rehm M, Conzen P. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008 Sep 4; 359 (10): 1071
129. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008 May; 35 (5): 458-68 (Pubitemid 351601995)
130. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008 May 29; 358 (22): 2332-43 (Pubitemid 351749157)
131. Mackey AC, Green L, Greene P, et al. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 2010 Jul; 40 (1): e1-3
132. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction: a 21-day treatment-randomized clinical trial. J Pain 2005 Mar; 6 (3): 184-92 (Pubitemid 40365022)
133. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008 Jul 15; 137 (2): 428-40
134. Etropolski M, Kelly K, Okamoto A, et al. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxy-codone hydrochloride. Adv Ther 2011 May; 28 (5): 401-17
135. Hale M, Upmalis D, Okamoto A, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009 May; 25 (5): 1095-104
136. Hupfeld S, Gravem H. Transdermal therapeutic systems for drug administration [in Norwegian]. Tidsskr Nor Laegeforen 2009 Mar 12; 129 (6): 532-3
137. Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther 2009 Oct; 26 (10): 920-35
138. Brown MB, Martin GP, Jones SA, et al. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006 May; 13 (3): 175-87
139. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005 Mar; 29 (3): 297-326 (Pubitemid 40386746)
140. Park JH, Kim JH, Yun SC, et al. Evaluation of efficacy and safety of fentanyl transdermal patch (Durogesic D-TRANS) in chronic pain. Acta Neurochir (Wien) 2011 Jan; 153 (1): 181-90
141. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997 Jan; 53 (1): 109-38 (Pubitemid 27042235)
142. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life: the TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997 May; 13 (5): 254-61 (Pubitemid 27240678)
143. Shipton EA. Shipton EA Safety and tolerability of buprenorphine. In: Budd K, Raffa R, editor. Buprenorphine: the unique opioid analgesic. Stuttgart: Thieme Verlag KG, 2005: 92-101
144. Cryer B, Katz S, Vallejo R, et al. A phase 3, randomized, double-blind, placebo-controlled clinical trial of lubipros-tone for the treatment of opioid-induced bowel dysfunction in patients with chronic, non-cancer pain [abstract no. 906]. Gastroenterology 2010; 138 Suppl. 1: S-129